Referências

1. Giovannoni G, Turner B, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015 Jul;4(4):329-33. doi: 10.1016/j.msard.2015.04.006. 2. Pandit L. Ann Indian Acad Neurol. 2019;22(3):261–263. 3. Medline Plus. Multiple sclerosis. Disponível em: https://medlineplus.gov/ency/article/000737.htm (Acessado em novembro de 2024). 4. MS Society. Relapsing remitting MS. Disponível em: https:// www.mssociety.org.uk/about-ms/types-of-ms/relapsing-remitting-ms (Acessado em novembro de 2024). 5. De Stefano N, et al. Arch Neurol. 2001;58:65–70. 6. Lublin FD, et al. Neurology. 2003;61:1528–1532. 7. Jones E, et al. BMC Health Serv Res. 2016;16:294. 8. Sormani MP, Bruzzi P. Lancet Neurol. 2013;12:669–676. 9. Smith AL, et al. Neurotherapeutics. 2017;14:952–960. 10. Z iemssen T, et al. J Neurol. 2016;263:1053–1065. 11. F ernandez O. Mult Scler Relat Disord. 2017;17:75–83. 12. H arding K, et al. JAMA Neurol. 2019;76:536–541. 13. M erkel B, et al. Autoimmun Rev. 2017;16:658–665. 14. Robertson D, Moreo N. Fed Pract. 2016;33:28–34. 15. G iovannoni G, et al. Mult Scler Relat Disord. 2016;9 Suppl 1:S5–S48.